Zepbound (Tirzepatide) Zepbound utilizes dual hormone action on GLP-1 and GIP, targeting significant weight loss
CPGs must move to 'bar code marketing' with focused efforts on improving product ingredients given this GLP-1 rise and the growth of health apps like YUCA
Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: an effect of glucosylceramide accumulation
Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer major events at both 3 and 6 months compared to those receiving a placebo, often before most had reached the full target dose
Off-label prescribing happens all the time in medicine, so its not necessarily a malicious or negligent type of thing, Narang said
This is why many people look to medical weight loss as the next step